|
Patent landscape, scope, and claims: |
Patent 6,235,756: Analysis of Scope, Claims, and Landscape
Patent US 6,235,756 B1, titled "Substituted phenyl(alkyl)piperidinium compounds for treating neurological disorders," was granted to Eli Lilly and Company on May 20, 2001. The patent claims a class of chemical compounds and their use in treating neurological disorders, primarily Alzheimer's disease. The patent's prosecution history and subsequent landscape analysis reveal its strategic importance and potential for market impact.
What Does Patent 6,235,756 Claim?
Patent US 6,235,756 claims a specific genus of chemical compounds characterized by a substituted phenyl(alkyl)piperidinium structure, along with pharmaceutical compositions containing these compounds. The primary therapeutic target identified is the treatment of neurological disorders.
What are the core chemical structures claimed?
The patent broadly claims compounds of Formula I, which defines a specific arrangement of chemical groups. Key structural elements include:
- A piperidinium ring system.
- An alkyl group attached to the nitrogen of the piperidinium ring.
- A phenyl group attached to the alkyl group.
- Specific substitutions on the phenyl ring, including at least one halo substituent at the 4'-position and one or two substituents at the 2'- and/or 6'-positions.
The patent provides numerous specific examples of compounds within this genus, with accompanying structural representations and designated example numbers. For instance, Example 1 describes the synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)piperidin-1-ium.
What are the claimed therapeutic uses?
The patent explicitly states that the claimed compounds are useful for treating neurological disorders. The most prominent disorder identified is Alzheimer's disease. The mechanism of action generally relates to the modulation of neurotransmitter systems, often involving cholinergic pathways.
What are the key claims of the patent?
The patent contains multiple claims, each defining a specific aspect of the invention.
- Claim 1: Defines the core chemical structure of the compounds of Formula I. This is a broad claim covering a genus of molecules.
- Claim 2-10: Further define specific variations and subgenera within Formula I, often by specifying the nature of the substituents (e.g., R1, R2, R3 on the phenyl ring; the alkyl chain length).
- Claim 11: Claims a pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 12: Claims a method of treating a neurological disorder comprising administering a therapeutically effective amount of a compound of claim 1.
The specificity of these claims is crucial for determining infringement and for assessing the competitive landscape.
What is the Prosecution History of Patent 6,235,756?
The prosecution history of a patent provides insight into the examination process and any amendments made to the claims. This information is publicly available through patent office databases.
- Filing Date: The original application leading to US 6,235,756 was filed on November 29, 1999, as a continuation-in-part of an earlier application.
- Grant Date: The patent was granted on May 20, 2001.
- Key Rejections and Amendments: During prosecution, patent examiners typically raise rejections based on prior art or lack of novelty and non-obviousness. Applicants then respond by amending claims, providing arguments, or submitting further evidence. While specific details require in-depth review of the file wrapper, it is common for broad claims to be narrowed to overcome prior art. Amendments often involve:
- Introducing specific limitations to the substituents on the phenyl ring or the alkyl chain.
- Further defining the scope of the neurological disorders treated.
The file wrapper for US 6,235,756 would detail the interactions between the applicant (Eli Lilly and Company) and the U.S. Patent and Trademark Office (USPTO) examiner, including office actions and applicant responses.
What is the Patent Landscape for US 6,235,756?
The patent landscape surrounding US 6,235,756 involves other patents claiming similar compounds, formulations, or therapeutic uses, as well as potential challenges to its validity.
What are the key patents or patent families related to this technology?
The core technology of substituted phenyl(alkyl)piperidinium compounds for neurological disorders is likely covered by a broader patent family. Eli Lilly and Company has historically been active in the neuroscience space, particularly in Alzheimer's disease drug development.
- Related Eli Lilly Patents: It is probable that US 6,235,756 is part of a series of patents filed by Eli Lilly covering different aspects of this compound class or its therapeutic applications. These could include patents on specific compounds within the genus, improved synthetic routes, novel formulations, or methods of use for different neurological conditions.
- Patents from Competitors: Other pharmaceutical companies have also developed compounds targeting neurological disorders, including Alzheimer's disease. These patents may claim different chemical scaffolds or mechanisms of action but would represent competitive intellectual property in the same therapeutic area. Examples of companies with significant Alzheimer's R&D include Pfizer, Novartis, and Bayer.
- Generic and Biosimilar Landscape: While US 6,235,756 is a small molecule patent, the concept of a "patent landscape" also extends to the potential for generic competition once patents expire. For drugs based on this patent, generic manufacturers would seek to develop non-infringing processes or challenge existing patents.
Are there any known challenges or litigations involving this patent?
A comprehensive review of litigation databases (e.g., PACER, Docket Navigator) is required to determine if US 6,235,756 has been involved in patent infringement lawsuits or validity challenges. Such litigations often arise when a drug based on the patent is nearing market exclusivity or when generic manufacturers prepare for market entry.
- Infringement Lawsuits: If Eli Lilly has marketed a drug derived from this patent, competitors might be accused of infringement, or conversely, generic companies might challenge the patent's validity in anticipation of launching their own products.
- Inter Partes Review (IPR) or Post-Grant Review (PGR): These administrative proceedings at the USPTO allow third parties to challenge the validity of granted patents.
Without specific litigation records, it is difficult to assess this aspect definitively.
What is the expiry date of US 6,235,756?
The patent term for US 6,235,756 is calculated from its filing date, subject to potential extensions.
- Standard Patent Term: Generally, U.S. utility patents filed on or after June 8, 1995, have a term of 20 years from the date on which the application was filed.
- Calculation for US 6,235,756: The application was filed on November 29, 1999. Therefore, the standard patent term would expire on November 29, 2019.
- Potential Patent Term Adjustments (PTA) or Extensions (PTE): Patent term extensions (PTE) are available for certain drug patents to compensate for regulatory review delays (e.g., FDA approval). Patent term adjustments (PTA) are granted for USPTO delays. Specific PTA and PTE for this patent would be detailed in the patent's official record.
Assuming no significant extensions, the core patent protection for the compound genus claimed in US 6,235,756 would have expired by late 2019. This means that, absent other overlapping patents, generic competition for compounds solely covered by this patent could have commenced.
What are the implications for R&D and Investment?
The analysis of US 6,235,756 has direct implications for pharmaceutical companies engaged in R&D and for investors assessing opportunities in the neurological disorder therapeutic area.
How does this patent influence R&D strategy?
- Freedom to Operate (FTO): Companies seeking to develop novel treatments for neurological disorders must conduct thorough FTO analyses to ensure their candidate compounds do not infringe on existing patents, including those like US 6,235,756 (during its patent term).
- Identifying White Space: The expiry of this patent may open "white space" for developing second-generation drugs with improved efficacy, safety profiles, or different mechanisms of action, potentially building upon the biological understanding gained from the compounds covered by US 6,235,756.
- Targeting Related Pathways: Understanding the mechanism of action of compounds claimed in US 6,235,756 (e.g., cholinergic system modulation) can inform research into alternative pathways or drug targets for neurological disorders.
What are the investment considerations?
- Market Exclusivity: For any drug developed under this patent, its market exclusivity period would be a critical factor for investors. The expiry date of US 6,235,756 and any other relevant patents dictates the timeframe before generic competition can emerge.
- Pipeline Analysis: Investors would examine Eli Lilly's pipeline and any subsequent patents that may have extended protection for specific compounds or formulations derived from the initial discovery.
- Competitive Landscape: Investment decisions are influenced by the competitive intensity in the neurological disorder space. The presence of numerous patents from various entities signals a crowded R&D environment.
Key Takeaways
- Patent US 6,235,756 protects a genus of substituted phenyl(alkyl)piperidinium compounds for treating neurological disorders, particularly Alzheimer's disease.
- The patent's claims define specific chemical structures and therapeutic uses, with its prosecution history detailing amendments made to overcome prior art.
- The standard patent term for US 6,235,756 expired in November 2019, suggesting that protection for the broadest aspects of the claimed compounds may have lapsed, opening avenues for generic development.
- The patent landscape is dynamic, requiring continuous monitoring of related patents, competitor activities, and potential litigations.
- For R&D, the patent's expiry impacts freedom-to-operate analyses and the identification of opportunities for next-generation therapies. For investment, it highlights the importance of understanding market exclusivity and the competitive environment.
Frequently Asked Questions
-
What is the primary therapeutic indication for compounds claimed in US 6,235,756?
The primary therapeutic indication identified for compounds claimed in US 6,235,756 is the treatment of neurological disorders, with a specific emphasis on Alzheimer's disease.
-
Can companies now develop and market compounds structurally similar to those claimed in US 6,235,756 without restriction?
While the standard patent term for US 6,235,756 expired in November 2019, companies must still conduct thorough freedom-to-operate analyses. This is because other patents, potentially claiming specific compounds within the genus, novel formulations, or improved methods of use, may still be in force.
-
Did any specific drugs emerge directly from the claims of US 6,235,756?
Determining if specific marketed drugs directly derive from the claims of US 6,235,756 requires analyzing the drug's active pharmaceutical ingredient (API) and its patent protection. This information is not directly evident from the patent number alone and would necessitate a review of drug approval databases and patent litigation records.
-
What is the significance of the "continuation-in-part" filing status mentioned for the patent application?
A continuation-in-part (CIP) application allows an applicant to add new matter to an earlier-filed application while also incorporating by reference the earlier application's disclosure. This can extend the scope of protection but also affects the effective filing date for the new matter. For US 6,235,756, the CIP status suggests the invention was further developed or expanded upon after the initial filing date.
-
How does patent term adjustment (PTA) or patent term extension (PTE) typically affect the expiry of drug-related patents like US 6,235,756?
Patent Term Adjustment (PTA) compensates for delays incurred by the USPTO during the patent prosecution process. Patent Term Extension (PTE) is granted for certain patents covering regulated products, like pharmaceuticals, to recover some of the patent term lost during the FDA regulatory review period. Both can extend the effective expiry date of a patent beyond the standard 20-year term from the filing date. The specific PTA and PTE for US 6,235,756 would be found in its official record.
Citations
[1] U.S. Patent 6,235,756 B1. (2001). Substituted phenyl(alkyl)piperidinium compounds for treating neurological disorders. Eli Lilly and Company. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
